Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H48N4O4S |
Molecular Weight | 644.866 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C2C=C(SC2=C1)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC6CCOCC6)CC5
InChI
InChIKey=YQYSVMKCMIUCHY-WJOKGBTCSA-N
InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1
Molecular Formula | C37H48N4O4S |
Molecular Weight | 644.866 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Menarini was developing ibodutant (also known as MEN15596) as a selective neurokinin (NK) 2 and tachykinin receptor antagonist. It is known that tachykinins have been implicated in the pathophysiology of irritable bowel syndrome (IBS) with diarrhoea. Ibodutant was studied as a treatment for gastrointestinal disorders. A phase 2 trial completed in May 2012 with positive results. Ibodutant participated in a 52-week phase 3 in women with IBS with diarrhea, however, the study was terminated because of the negative results of the sister study NAK-06 and the low overall response rate at week 24.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21452 Gene ID: 6865.0 Gene Symbol: TACR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19218528 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02120027
Ibodutant 10 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:30:04 GMT 2023
by
admin
on
Fri Dec 15 18:30:04 GMT 2023
|
Record UNII |
1H7RSQ28BJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
522664-63-7
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
8909
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
11527495
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
1H7RSQ28BJ
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
C556791
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
IBODUTANT
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
300000037039
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL266125
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
C166502
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
DB12042
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY | |||
|
DTXSID20966639
Created by
admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|